Intranasal delivery of NS1-deleted influenza virus vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response
L. Zhang, Y. Jiang, J. He, J. Chen, R. Qi, L. Yuan, T. Shao, C. Chen, Y. Chen, X. Wang, X. Lei, Q. Gao, C. Zhuang, M. Zhou, J. Ma, , N. Xia
This study evaluates an intranasal influenza-based vaccine against SARS-CoV-2 variants, showing it reduces inflammatory response and tissue damage through local immunity.
bioRxiv · Oct 3, 2022 · PreprintImmunology